FDA Finds No Increased Risk of MI, Stroke With Use of Tiotropium Bromide Inhalation Powder
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Finds No Increased Risk of MI, Stroke With Use of Tiotropium Bromide Inhalation Powder

ROCKVILLE, Md -- January 14, 2010 -- The US Food and Drug Administration (FDA) has announced that data from a recent review of tiotropium bromide inhalation powder (Spiriva HandiHaler), a long-acting respiratory treatment for chronic obstructive pulmonary disease (COPD), do not support an increased risk of stroke, myocardial infarction (MI) or death in patients using the medicine.

A March 2008 FDA Early Communication had described data submitted by the manufacturer of the tiotropium bromide inhalation powder as suggesting a small increased risk of stroke in patients treated with tiotropium.

In October 2008, an Updated Early Communication highlighted 2 additional publications suggesting an increased risk of stroke, MI, and death in patients using tiotropium.

Today’s update of those communications is based on an FDA review of the Understanding the Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) study, which compared tiotropium bromide inhalation powder with a placebo in 5,992 patients with COPD.

In November 2009, the FDA Pulmonary - Allergy Drugs Advisory Committee also reviewed the data and voted that findings from the UPLIFT study resolved the potential safety concerns for tiotropium bromide inhalation powder.

SOURCE: US Food and Drug Administration

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities